Filing Details

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

Schedule 13D

Under the Securities Exchange Act of 1934

(Amendment No. 8)

 

 

EXICURE, INC.

(Name of Issuer)

Common Stock, par value $0.0001 per share

(Title of Class of Securities)

30205M200

(CUSIP Number)

Kyungwon Oh

Chief Executive Officer

CBI USA, Inc.

c/o Baker & Hostetler LLP

One North Wacker Drive, Suite 4500

Chicago, IL 60606-2841

Attention: Jonathan Park

(312) 416-6200

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

May 15, 2023

(Date of Event which Requires Filing of this Statement)

 

 

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §240.13d-1(e), §240.13d-1(f) or §240.13d-1(g), check the following box:  ☐

The information required on the remainder of this cover page shall not be deemed to be filed for the purpose of Section 18 of the Securities Exchange Act of 1934 (Act) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

 

 

 

SCHEDULE 13D

CUSIP No. 30205M200

 

1.		Name of Reporting Person     CBI USA, Inc.
2.		Check the Appropriate Box if a Member of a Group   (a)  ☐        (b)  ☐
3.		SEC Use Only
4.		Source of Funds (See Instructions)     WC, AF
5.		Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)     ☐   Not Applicable
6.		Citizenship or Place of Organization     Delaware

Number of Shares  Beneficially  Owned by Each Reporting Person With				7.		Sole Voting Power     4,218,299
				8.		Shared Voting Power     0
				9.		Sole Dispositive Power     4,218,299
				10.		Shared Dispositive Power     0

11.		Aggregate Amount Beneficially Owned by Each Reporting Person     4,218,299
12.		Check if the Aggregate Amount in Row (11) Excludes Certain Shares     ☐
13.		Percent of Class Represented by Amount in Row (11)     50.4%(1)
14.		Type of Reporting Person     CO

 

(1)	Percentage ownership based on 8,366,715 shares outstanding as reported in the Companys Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 27, 2023.

SCHEDULE 13D

This Amendment No. 8 (Amendment No. 8) amends and supplements the Schedule 13D filed with the Securities and Exchange Commission (the SEC) on June 1, 2022 (the Initial Schedule 13D and together with Amendment No. 1 thereto filed with the SEC on October 31, 2022 (Amendment No. 1), Amendment No. 2 thereto filed with the SEC on December 5, 2022 (Amendment No. 2), Amendment No. 3 thereto filed with the SEC on December 19, 2022 (Amendment No. 3), Amendment No. 4 thereto filed with the SEC on January 23, 2023 (Amendment No. 4), Amendment No. 5 thereto filed with the SEC on February 13, 2023 (Amendment No. 5), Amendment No. 6 thereto filed with the SEC on March 3, 2023 (Amendment No. 6), and Amendment No. 7 thereto filed with the SEC on May 1, 2023 (Amendment No. 7), the Schedule 13D) by CBI USA, Inc. (the Reporting Person) with respect to the Common Stock, par value $0.0001 per share, of Exicure, Inc. (Exicure or the Company). Capitalized terms used herein and not otherwise defined in this Amendment No. 8 shall have the meanings set forth in the Schedule 13D. This Amendment No. 8 amends Items 4 and 7 to the extent set forth below.

Item 4. Purpose of the Transaction

Item 4 is supplemented as follows:

On May 15, 2023, the Reporting Person and CBI Co sent a letter to the board proposing that each of Jo, Ahn and Kim resign due to their continuing failure to act in the interests the Company and the stockholders and be replaced by designees of the Reporting Person. The letter also notified the board that the Reporting Person and CBI Co would promptly pursue all available legal options if the requested action is not taken. A copy of the letter is attached as Exhibit 2.

Item 7. Material to be Filed as Exhibits.

Item 7 is supplemented by adding the following exhibits:

 

Exhibit No.		Name
2.		Letter to the Board

SIGNATURES

After reasonable inquiry and to the best of its knowledge and belief, the undersigned hereby certify that the information set forth in this statement is true, complete and correct.

Date: May 16, 2023